Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Timing of EGD After Lidocaine Spray
NCT06497296Recruiting
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of lidocaine 10% oropharyngeal spray in dyspepsia, Peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD) and 1 more (2 arms), sponsored by National Cheng Kung University Hospital. Primary endpoints: Heart rate change at 1 day and Blood pressure change at 1 day. Started Jan 2023; status: recruiting.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
dyspepsiaPeptic ulcer disease (PUD)gastroesophageal reflux disease (GERD)diarrhea
Beyond the preview
Go deeper on NCT06497296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497296.